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1. Introduction 
Renal replacement therapy (RRT), including various delivery types of haemodialysis, has 
revolutionised the care of patients with end stage renal disease (ESRD). The most common 
RRT modality is haemodialysis (ANZ Data 2010, Boddana et al., 2009). Access for dialysis is 
via arteriovenous fistulae (AVF), arteriovenous grafts (AVG) or via central venous dialysis 
catheters. The goal of access is to provide a means of accessing the vasculature to undertake 
RRT in order to deliver the optimal dialysis dose with the minimal associated morbidity and 
mortality. The National Kidney Foundation (NKF) Kidney Disease Outcome Quality 
Initiative (KDOQI, 2006) guidelines recommend an AVF prevalence rate of greater than 
65%. Arteriovenous fistulae remain the preferred method of access due to improved 
survival rate and lower associated morbidity and associated medical costs (NKF-KDOQI, 
2006). Despite all these measures, dialysis catheters remain commonly used for a variety of 
reasons. They are now well acknowledged as the harbinger of potential future significant 
morbidity and mortality. 
As a result of the significant morbidity burden caused by dialysis catheters, there has been 
great interest in discovering new and inventive methods of reducing catheter-related 
infection. Out of this is borne the investigation of preventative measures outlined here. This 
is particularly important given the immunosuppressed nature of renal patients. The 
evidence for, and utility of measures, such as topical antimicrobial ointment application, 
antimicrobial catheter lock solutions, antibiotic impregnated catheters, differing AVF 
cannulation methods and catheter design, shall be explored below.  
As we strive for improved outcomes in our patients many more patients are undertaking 
extended hours home haemodialysis. In those patients with the lowest risk accesses, 
questions have been raised as to the method of access cannulation and the spectre of 
increasing associated infectious events. The rope ladder technique involves regular 
rotation of cannulation sites whereas buttonhole technique uses the same cannulation 
sites and relies on formation of a track which is then repetitively accessed with blunt 
needles. This has been a very attractive method for home dialysis patients for a range of 
reasons. However, despite recent popularity with this technique, a number of studies 
including from our centre, have now shown that this technique is associated with 
increased septic events (Birchenough et al., 2008; Nesrallah et al., 2010; Van Eps et al., 
2010; Van Loon et al., 2010).  
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2. Vascular access 
Vascular access remains a predominant cause of morbidity in haemodialysis patients. There 
is significant global variation in the use of the different types of haemodialysis access. There 
have now been a number of studies examining trends of access use (Ethier et al., 2008; Pisoni 
et al., 2002) and further, epidemiological associations between access type and outcomes 
(Dhingra et al., 2001; Ishani et al., 2005; Moist et al., 2008; Pastan et al., 2002; Polkinghorne et 
al., 2004; Xue et al., 2003). 
2.1 Geographical and temporal trends in access use 
Pisoni et al., (2002) in the Dialysis Outcomes and Practice Patterns Study (DOPPS) 
confirmed significant variations in access practice between Europe and the United States. 
The practice comparison found that AVFs were much more common in prevalent patients in 
Europe, while AVGs and catheters were more commonly used in the US. Arteriovenous 
fistulae were used in 80% of the European prevalent population compared with only 24% of 
US prevalent populations and the use was associated with younger male patients with 
fewer co-morbidities. Use in incident patients varied from 66% in Europe to only 15% in the 
US. Conversely, AVGs and catheters were more common in incident patients in the US 
compared to Europe (2% versus 24% and 60% versus 31% respectively). Dialysis catheters 
were the first modality of access at commencement of dialysis in the US (Pisoni et al., 2002). 
Trends in vascular access have changed over time but have shown a progression towards 
AVF use. Data from DOPPS I (1996-2001), DOPPS II (2002-2004) and DOPPS III (2005-2007) 
were compared and found that trends towards increasing AVF use were observed in 
Australia, New Zealand and the United Kingdom. Australia and New Zealand have 
traditionally had higher rates of AVF use. Arteriovenous fistulae in these countries, along 
with Japan and most European countries (excluding the United Kingdom, Belgium and 
Sweden), are used in over 70% of prevalent haemodialysis patients. The use of AVFs had 
increased significantly in the US in the same time from 24% in DOPPS I to 47% by DOPPS III 
(Ethier et al., 2008). Most recent data available shows that AVF use in the US is now greater 
than 57% (www.fistulafirst.org). In all the countries studied, AVG use remained stable or 
declined. The US showed the greatest decline in prevalent patient use, falling from 58% in 
DOPPS I to 29% in DOPPS III (Ethier et al., 2008). 
Despite efforts to improve outcomes for ESRD patients, dialysis catheters remain a 
predominant form of vascular access well into the 21st century. Dialysis catheters were 
observed in greater than 20% of prevalent patients in the UK, Belgium, Sweden, Canada, 
and the US. A 2- to 3-fold increase in catheter use was observed in Italy, Germany, France 
and Spain by DOPPS III (Ethier et al., 2008). Catheter use will never be completely 
eliminated as they have a significant role in those patients who require urgent dialysis and 
for whom no other access exists. There is often regional variation in access practice patterns. 
The reasons for this appear to be multifactorial and include variables such as patient 
preference, surgical wait times, surgical expertise, as well as physician and nursing factors 
(Polkinghorne, et al., 2004). 
2.2 Epidemiological aspects of access type 
A number of studies have now shown an epidemiological association between access type 
and outcome. Use of venous catheters and AVGs over native AVFs has been shown to carry 
higher human costs. A number of studies have shown an association between catheter use 
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and increased mortality from both infective and non-infective causes (Dhingra et al., 2001; 
Pastan et al., 2002; Polkinghorne et al., 2004). One study analysed a random sample of 
patients from the U.S. Renal Data System Dialysis Morbidity and Mortality Study (USRDS) 
Wave 1. Both diabetics and non-diabetics with catheters demonstrated similar trends in 
survival. The best overall survival was observed with AVF over AVG. The poorest survival 
was seen in patients  with catheters (Dhingra et al., 2001). This increased mortality observed 
with AVGs and catheters has been replicated in a number of studies (Pastan et al., 2002; 
Polkinghorne et al., 2004; Xue et al., 2003). One of the largest investigations of access-related 
mortality included over 60,000 patients from the United States (Xue et al., 2003). The use of 
catheters at iniation of dialysis was associated with the greatest mortality risk (catheter 
hazard ratio [HR] 1.70, 95% CI 1.59-1.81; AVGs HR 1.16, 95% CI 1.08-1.24; AVF reference). . 
In this study, greater than 50% of patients commenced dialysis with a catheter.  
A prospective study of almost 1000 patients in France looked at the risk factors for 
development of bacteraemia in chronic haemodialysis patients (Hoen et al., 1998). This again 
confirmed that the greatest risk factor for bacteraemia was use of a dialysis catheter, with an 
incidence of 0.93 episodes of bacteraemia per 100 patient months. Multivariate analysis 
confirmed vascular access as a major risk factor for bacteraemia. Catheter use for 
haemodialysis carried a relative risk of bacteraemia of greater than 7 times that of an AVF 
(relative risk [RR] 7.6, 95% CI 3.7-15.6). Arteriovenous grafts carried only a marginally 
higher relative risk compared to AVFs. 
Access-related bacteraemia has also been shown to be an important factor in the subsequent 
development of cardiovascular-related morbidity and mortality. Where cause-specific 
mortality was assessed, increases in both infectious deaths (Dhingra et al., 2001; Ishani et al., 
2005; Pastan et al., 2002; Polkinghorne et al., 2004) and cardiac deaths were also observed 
(Dhingra et al., 2001; Ishani et al., 2005). Interestingly, in one study, non-diabetics using 
catheters at the inception of dialysis had a worse survival rate than those patients using 
permanent vascular access, with the difference being detectable after only 2 months of 
observation. The overall relative risk of infection-related death was approximately 2-fold 
higher in patients with central venous catheters over those with AVFs and was more 
marked in diabetics than non-diabetics. The risk of death from cardiac causes was 
approximately 1.5-fold higher in those with dialysis catheters (Dhingra et al., 2001). A 
prospective cohort study of incident dialysis patients in the U.S scrutinised the association 
between access modality and bacteraemia, and also the association between bacteraemia 
and cardiovascular events (Ishani et al., 2005). Cox regression analysis (n=2358) 
demonstrated that initial dialysis access was the main antecedent of septicaemia or 
bacteraemia. Long term dialysis catheters, temporary dialysis catheters and AVGs 
displayed HRs of 1.95, 1.76 and 1.05, respectively. The presence of bacteraemia or 
septicaemia was associated with heightened risks of subsequent cardiovascular morbidity 
and mortality. In those without defined coronary artery disease, a bacteraemic episode 
conferred a greater risk of death or acute cardiovascular event than those with pre-
existing cardiovascular disease. 
A study undertaken in Australia examined incident haemodialysis patients between 1999 
and 2002, and made further attempts to statistically adjust for  the non-random nature of 
access selection. This study found that those patients starting dialysis with a dialysis 
catheter or AVG had a greater risk of dying in the first 6 months compared to those with 
AVF; catheters being the most life-limiting of all three. This trend continued with time. 
Dialysing via an AVF showed a mortality rate of 86 per 1000 person-years; AVGs had a 
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mortality rate of 146 per 1000 person-years and catheters had the highest mortality rate of 
261 per 1000 person-years. Catheter use conferred 1.5- to 3-fold increased risks in both 
infectious and all-cause mortality. A similar trend in both increased infectious and all-
cause mortality with AVGs was also observed but not significant on analysis 
(Polkinghorne et al., 2004). 
Apart from catheter-related infectious mortality, proposed alternative mechanisms for the 
increased death rates in patients with catheters have included reduced dialysis doses 
delivered by central catheters and a higher prevalence of co-morbid conditions in patients 
who dialyse via catheters. However, the latter was not confirmed after controlling for 
vascular disease and congestive cardiac failure (Pastan et al., 2002). No patterns of catheter 
use associated with increasing age or existing co-morbidities were ascertained from the 
more recent DOPPS III analysis. The usage of dialysis catheters in younger (18-70 year old) 
non-diabetics increased 2-fold in the US and up to 3-fold in some European countries 
(France, Germany, Italy and Spain) (Ethier, et al., 2008). 
3. Incidence, pathogenesis and bacteriology of access-related infections 
Although the incidence of catheter-related bacteraemia is variable, the mean reported 
incidence is 3 episodes per 1000 catheter days (Dryden et al., 1991; Moss et al., 1990; Saad, 
1999; Mokryzcki et al., 2000; Mokrzycki et al., 2001). Data from the HEMO study (Eknoyan 
et al., 2008) indicates that patients with central venous catheters have an increased relative 
mortality risk of 3.4 when compared with patients with AVFs (relative mortality risk of 1.4). 
The burden of catheter-related infection is high, with reported rates of metastatic infectious 
complications (e.g. osteomyelitis, endocarditis, septic arthritis or epidural abscess) of 
between 10% and 40% (Marr et al., 1997; Maya et al., 2007; Neilsen et al., 1998). S. aureus is 
responsible for the majority of vascular access infections, accounting for 70-90% of cases (Del 
Rio el at., 2009; Gould, 2007).  
3.1 Catheter-related bacteraemia 
Gram-positive species are the culprit organisms in 61-95% of cases of catheter-related 
bacteraemia. In the prospective study by Hoen et al (1998), the most common causative 
organism was S. aureus. Coagulase-negative staphylococcal bacteraemia was almost as 
common as that caused by S. aureus. Escherichia coli and other aerobic gram negative bacilli 
were the next most commonly isolated organisms. The presumed portal of entry for these 
organisms was via the vascular access. In this study, 6 deaths were directly attributable to 
bacteraemia. The most common causative organisms under these circumstances were S. 
aureus and Pseudomonas with equal occurrence, and other Enterobacteriaciae making up the 
remainder of isolated agents (Hoen et al., 1998). 
Catheter-related bacteraemia may arise via two paths: (a) direct spread of microorganisms 
from the skin along the outside of the catheter leading to contamination of the 
bloodstream; or, (b) colonisation of the inner lumen of the catheter leading to the 
formation of biofilm and direct migration of organisms into the bloodstream. A biofilm is 
a multi-layered cell cluster with a strong propensity to adhere to polymer surfaces and 
provides a protected niche environment for microorganisms with physical barrier 
protection against antibiotics. Within the biofilm, bacteria exhibit increased growth rates, 
a higher cell density and more active gene transcription. This further contributes to the 
heightened resistance of bacteria to antibiosis (Fux et al., 2003). Even in the absence of 
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overt infection, microbial colonisation of catheters may engender a chronic inflammatory 
state, which in turn increases the risk of erythropoietin-resistant anaemia, malnutrition 
and cardiovascular disease (Barraclough et al., 2009).       
3.2 Arterio-venous fistula bacteraemia 
In those with AVF infection, S. aureus and Staphylococcus epidermis are most commonly 
responsible. Infection accounts for approximately one fifth of accesses being lost (Bhat et al., 
1980). Microorganisms gain entry to the bloodstream during cannulation. In addition, the 
presence of pseudoaneuryms, peri-access haematomas, non-functioning clotted fistulae and 
manipulation of AVFs during non-dialysis interventions increase the risk of infection 
(Barraclough et al., 2009).  
Recent evidence suggests that cannulation technique may have an important effect on the rates 
of bacteraemia related to AVFs. Over the last 30 years, the buttonhole cannulation technique 
has become increasingly popular. This technique involves repetitive cannulation of a small 
number of puncture sites, with the aim of creating a tunnel track into which the needles can be 
easily inserted. There are a number of benefits associated with using buttonhole cannulation 
for haemodialysis, particularly in the home environment. These benefits include easier and 
quicker needle insertion, less painful cannulation with the elimination of anaesthetic, 
reduction in “bad sticks”, and reduction in hematoma formation (Doss et al., 2008; Hartig and 
Smyth, 2009). The alternative cannulation method, referred to as the rope ladder technique, 
involves needle puncture along the length of the fistula and is more inclined to give rise to 
small dilatations over the length of the fistula. However, several studies have suggested that 
the buttonhole technique is associated with an increased risk of access-related infection 
compared with the rope ladder method. Birchenough et al. (2008) established a positive 
correlation between use of the buttonhole cannulation technique and an increased risk for 
infection in adult patients on haemodialysis. Nesrallah et al. (2010) observed a significantly 
increased risk of S. aureus bacteremia infection with potentially fatal metastatic complications 
in patients receiving home nocturnal haemodialysis with buttonhole cannulation. They 
recommended advising prospective patients of the infection risks, and, in the absence of more 
rigorous studies, giving consideration to topical Mupirocin prophylaxis. Other studies have 
similarly reported increased access-related infection rates in association with buttonhole 
cannulation (Ludlow, 2010; Silva et al., 2010; Van Loon et al., 2010).  
A subsequent retrospective observational cohort study in our unit involving 63 alternate 
nightly nocturnal haemodialysis and 172 conventional haemodialysis patients reported a 
statistically significant and clinically important increase in septic dialysis access events when 
nocturnal haemodialysis and buttonhole cannulation were used simultaneously (incidence 
rate ratio 3.0, 95% CI 1.04-8.66, p=0.04) (Van Eps et al., 2010). It is theorised that chronic 
bacterial colonisation of the buttonhole site may be the precursor to systemic infection, and 
that fibrosis surrounding the site may not provide as efficient a barrier as seen in those 
employing the rope ladder technique. This study highlights that increased infection control 
steps may be crucial in the setting of nocturnal haemodialysis and buttonhole technique.  
4. Preventative measures against access-related infection  
4.1 Aseptic technique 
The method of handling the dialysis catheter is crucial. Stringent aseptic techniques must be 
employed, with KDOQI 2006 recommending washing the access site with antibacterial scrub 
and water followed by cleansing of the skin with 2% chlorhexidine/alcohol or 70% alcohol. 
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A multicentre prospective randomised trial (n=849) compared chlorhexidine-alcohol with 
povidone-iodine in the setting of post-operative surgical wounds and found that the 
chlorhexidine-alcohol preparation was associated with a significantly lower rate of surgical 
site infection (9.5% vs 16.1%, p=0.004, RR 0.59, 95% CI 0.41 – 0.85). However, in dialysis 
populations, there are only a few RCTs detailing the value of different antiseptic ointments. 
A small RCT studying povidone-iodine in subclavian catheters demonstrated a statistically 
significant improvement in exit site infections (5% vs 18%, p<0.02), tip colonisations and 
incidence of septicaemia compared with using sterile gauze dressings alone in the control 
group (Levin et al., 1991). The beneficial effect of povidone-iodine ointment was most 
marked in those with S. aureus nasal carriage (3-fold higher risk of subclavian catheter-
related septicaemia, p<0.05). No significant increase in adverse effects was observed with 
povidone-iodine. 
There is no particular dressing type that has shown benefit over another. A chlorhexidine-
impregnated foam dressing has not been found to provide extra protection against infection 
in an open labelled study (Camins et al., 2010), despite previous evidence to the contrary in 
patients in an intensive care setting (Timsit et al., 2009). 
Maximal sterile barrier precautions were further studied in a recent Korean study. Using 
multivariate analyses, they found that the use of maximally sterile barrier precautions (odds 
ratio 5.205 95% CI 0.015 – 1.130, p=0.23) and use of antimicrobial coated catheters (odds ratio 
5.269 95% CI 0.073 – 0.814, p=0.022) were independent factors associated with a lower risk of 
acquiring a central venous catheter-related bacteraemic episode (Lee at al., 2008). In another 
single centre study, the institution of a catheter monitoring system and a formal 
maintenance program following catheter insertion was associated with a reduction in the 
occurrence of catheter-related bacteraemia by 33% (Yoo et al., 2001). A Cochrane systematic 
review of randomised controlled trials (McCann and Moore, 2010) reported that transparent 
polyurethane dressing did not reduce the risk of catheter-related exit site infection or 
bacteraemia compared to dry gauze. 
4.2 Catheter care protocols 
It is well accepted practice in the critical care sector to adopt a strictly protocolised approach 
to the care of central venous catheters (Beathard and Urbanes, 2008; Pronovost et al., 2010). 
Care bundles are commonly used in the intensive care unit. A “care bundle” is a set of 
evidence-based interventions that are administered to many intensive care patients, with the 
aim of risk reduction. There is no randomised trial evidence in the haemodialysis 
population, but prospective observational data has shown a marked reduction in 
bacteraemic episodes from 6.7 to 1.6 per 1000 catheter days over a twenty four month study 
period using an infection prophylaxis protocol based on NKF-K/DOQI guidelines (2001). 
The main focus of the protocol was strict cleansing of the catheter hub at the time of use in 
the dialysis facility to avoid any potential contamination. Other vital elements to catheter 
care include the technical placement of the catheter, exit site care and the handling of 
dialysis connections.       
4.3 Topical antimicrobial agents 
Use of topical antimicrobial agents has been associated with reduced rates of bacteraemic 
episodes and catheter loss of any cause (Rabindranath et al., 2009). Our group was one of the 
first to demonstrate that topical exit site application of mupirocin, an antibiotic active 
against Gram-positive organisms, resulted in significantly fewer catheter-related 
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bacteraemias (7 vs 35%, p<0.01) and a longer time to first bacteraemia (log rank score 8.68, 
P<0.01) (Johnson et al., 2002). The beneficial effect of mupirocin was entirely attributable to a 
reduction in staphylococcal infection (log rank 10.69, P=0.001) and was still observed when 
only patients without prior nasal S. aureus carriage were included in the analysis (log rank 
score 6.33, P=0.01). Median catheter survival was also significantly longer in the mupirocin 
group (108 vs 31 days, log rank score 5.9, P<0.05). 
Recently, McCann & Moore (2010) published the results of their Cochrane systematic review 
in which they evaluated the benefits and harms of prophylactic topical antimicrobial agents 
on infectious complications among haemodialysis patients with central venous catheters. In 
a total of 10 randomised controlled trials involving 787 patients, the risk of catheter-related 
bacteraemia was reduced by topical exit site application of mupirocin (RR 0.17, 95%CI 0.07 - 
0.43), polysporin triple ointment consisting of bacitracin, gramicidin and polymixin B (RR 
0.40, 95% CI 0.19 – 0.86), and povidone-iodine ointment (RR 0.10, 95% CI 0.01 – 0.72). 
Mortalityrelated to infection was not reduced by any of these three agents.  
In another meta-analysis topical antimicrobial agents reduced the rates of bacteraemia (risk 
rate ratio 0.22, 95% CI 0.12 – 0.40), exit site infection (RR 0.17, 95% CI 0.08 – 0.38), 
requirement for catheter removal and hospitalisation for infection compared with no 
antibiotics (James et al., 2008). 
In spite of the demonstrated benefits of topical antimicrobial agents on catheter-associated 
infection rates, a real concern surrounding these agents is the potential risk of antibiotic 
resistance. Whilst these fears have not yet been realised, a number of groups have suggested 
that antimicrobial prophylactic therapy should be limited in duration and scope to minimise 
the possibility of promoting antimicrobial resistance. For example, a recent position 
statement issued by the European Renal Best Practice (ERBP) working group recommended 
the application of antimicrobial ointments (either mupirocin or polysporin ointment) after 
catheter placement only until the exit site has healed completely (Tordoir et al., 2007). They 
specifically advised against the use of these agents after the site has healed because of the 
fear of emerging resistance and Candida colonisation.  
4.4 Antimicrobial locks  
There is evidence that “locking” a catheter with a small amount of antimicrobial agent 
that remains within the catheter lumen can prevent bacteraemic episodes. These 
antimicrobial locks are thought to possess extra biofilm-removing properties. This is in 
contrast to heparin, which may serve to antagonise the antibacterial properties of certain 
antibiotics (Droste et al., 2003, Regamey et al., 1972) and may in fact promote biofilm 
formation (Shanks et al., 2006).  
Nine randomised controlled trials looked at the potential role of antimicrobial locks versus 
the standard heparin lock. The mean baseline risk of catheter-related infection was 3.0 
episodes per 1000 catheter days, with the catheter insertion duration ranging from 37-365 
days (mean 146 days). Seven out of 9 trials used an antibiotic, 1 used taurolidine and 1 used 
30% citrate. The different antimicrobial preparations included amikacin, cefazolin, 
cefotaxime, ciprofloxacin, EDTA, gentamicin, minocycline and vancomycin. Collectively, 
they showed a more than three-fold reduction in the occurrence of catheter-related 
bacteraemia, in addition to reductions in mortality and morbidity (Allon et al., 2008; Jaffer et 
al., 2008; Labriola et al., 2008;). Seven out of 9 of the studies reached statistical significance. 
The use of antimicrobial locks also significantly reduced the rate of catheter loss due to all 
complications (3 trials; n=399; RR 0.61, 95% CI 0.45-0.83) (Rabrinathan et al., 2009). 
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Unfortunately, most of these trials were of short duration, being limited to 12 months 
follow-up or less. Consequently, the long-term risk:benefit of antimicrobial locks is 
uncertain. Significant side effects of antimicrobial locks that have been documented in the 
above trials included hypocalcaemia (Power et al., 2009) digital parasthesiae (Power et al., 
2009) and ototoxicity in 10% of those using gentamicin based catheter locks (Dogra et al., 
2002). Moreover, there are significant concerns that long term use of antimicrobial locks may 
promote multiresistant organisms (MROs). An American unit using a gentamicin/heparin 
lock observed the appearance of gentamicin resistant bacteraemia after a period of 6 months 
(Landry et al., 2010). The most common complications following such bacteraemias were 
catheter removal and hospital admission. Thus, despite a 95% decrease in the rate of 
catheter-related bacteraemia, there was the emergence of gentamicin resistant gram negative 
infections with tunnelled catheters being the most common access in the group. After 
stopping the gentamicin antimicrobial lock, the resistance to gentamicin dropped after 18 
months. 
4.5 Non-antimicrobial locks 
4.5.1 Citrate  
The spectre of antibiotic resistance has led nephrologists to seek alternative catheter lock 
agents. Sodium citrate has been utilised as an alternative anticoagulant to intradialytic 
heparin. Anticoagulant activity is brought about by reducing the free plasma calcium 
concentration and thus retarding the coagulation cascade. A 30% citrate solution will have 
antimicrobial and antibacterial properties. Citrate does not promote bacterial resistance and 
therefore has been proposed as the ideal catheter lock solution (Bleyer, 2007). 
Power et al. (2009) studied 232 haemodialysis patients randomised to either 46.7% sodium 
citrate or 5% heparin locks post-dialysis for a 6 month period. In both groups, the rate of 
catheter-related bacteraemia was 0.7 events per 1000 catheter days with no significant 
difference between groups. There was a statistically significant increase in catheter 
thrombosis in the citrate group (p<0.001). All patients had a tunnelled twin catheter single 
lumen Tesio catheter. 
Weijiner et al. (2005) had previously shown an added benefit of Trisodium citrate 30% in a 
randomised controlled trial incorporating 291 randomised haemodialysis patients. In this 
group however, 98/291 (34%) and 193/291 (66%) possessed tunnelled cuffed catheters 
and non-tunnelled catheters respectively. Catheter-related infection rates were 1.1 per 
1000 catheter days in the trisodium citrate 30% group versus 4.1 per 1000 in the heparin 
group (p<0.001). There was found to be no difference in the rate of thrombotic events. 
This study showed a risk reduction for catheter-related bacteraemia of 87% for tunnelled 
catheters (p<0.001) and 64% for non-tunnelled catheters (p=0.05). There were fewer deaths 
from bacteraemia in the trisodium citrate 30% group (0 vs 5, p=0.028). Exit site infections 
were also reduced.  
A concern with use of citrate relates to its chelating properties that can lead to 
hypocalcaemia with subsequent risk of ventricular arrhythmias. The death of a patient in 
2000 from cardiac arrest following installation of 46.7% sodium citrate into a haemodialysis 
catheter prompted a Food and Drug Association (FDA) warning about its use (Food and 
Drug Administration, 2009). Many haemodialysis centres therefore avoid high doses of 
citrate in catheter locks. There is ongoing interest in using lower concentrations of sodium 
citrate, either alone or in combination with taurolidine or ethanol. 
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4.5.2 Taurolidine 
Taurolidine locks possess antimicrobial activity by producing methyl taurinamde products 
that bind to bacterial and fungal cell walls and cause damage. The antimicrobial effect is 
broad spectrum and has been shown to reduce the progression to biofilm production 
(Torres-Viena et al., 2000). There are no reports of antibiotic resistance. 
A randomised controlled trial from the United Kingdom randomised subjects to receive 
either Taurolidine-Citrate lock (1.35% taurolidine & 4% citrate) or unfractionated heparin 
5000units/mL. The primary outcome was time to first bacteraemic episode and secondary 
outcomes were total number of bacteraemic episodes and gram positive and gram negative 
infections. There was found to be no statistically significant difference in time to first 
bacteraemic episode (n=110). However, there was a significant reduction in gram negative 
infections (p=0.02). The main drawback to using Taurolidine-citrate locks is a greater need 
for thrombolytic therapy. Solomon et al. (2010) surmised that tauroldine-citrate usage 
impacted only infection of intraluminal origin and that better formulations with an 
improved anticoagulant profile should be sought. These findings echo those trends seen 
previously (Allon, 2003, Betjes and Van Agteren 2004; Taylor et al., 2008).  
4.5.3 Ethanol 
Ethanol is an effective disinfectant with a broad spectrum of activity against a host of micro-
organisms. Its benefits include low toxicity, lack of antibiotic resistance, ready availability 
and low cost. Ethanol-containing catheter locks were initially used in oncology patients to 
maintain long term catheters and in those receiving total parenteral nutrition in order to 
manage catheter occlusion (Ball et al., 2003; Metcalf et al., 2004; Pennington and Pithie, 
1987). As little as 60 minutes exposure to a 30% ethanol- 14% trisodium citrate locking 
solution has been show to effectively eradicate the common gram-positive and gram-
negative bacteria colonising catheters (Takla et al., 2007). Maharaj et al. (2008) demonstrated 
an equally impressive effect on Candida albicans isolates within the same time frame. These 
antimicrobial benefits of ethanol appear to be associated with a neutral effect on the 
integrity of catheter material. A recent small study tested found no negative effect of a 30% 
ethanol-4% sodium citrate locking solution on catheters (Vercaigne et al., 2010). Guenu et al. 
(2007) similarly found no deterioration in silicone catheter viability following exposure to 
high concentrations of ethanol. 
Our unit is currently conducting a randomised controlled trial of heparin versus ethanol 
lock for the prevention of catheter-associated infection (Broom et al., 2009). This is a single 
centre prospective open-label study comparing 3mL 70% ethanol catheter lock head to head 
with a standard heparin lock. Using time to first catheter-related bacteraemia as the primary 
outcome, the study will hopefully elucidate further the benefit of ethanol as a useful 
preventative measure against catheter-related infections. 
4.5.4 Honey 
The healing properties of honey have been recognised since antiquity. Ancient Greeks and 
Egyptians used honey to aid in the healing of burns and sores. During World Ward I 
German physicians used honey and cod liver oil together as a surgical dressing for battle 
wounds. The antimicrobial properties of honey are related to its very high sugar content, 
which kills bacteria through dessication, and enzymatic production of hydrogen peroxide 
(glucose + H2O + O2 → gluconic acids + H2O2). The enzyme glucose oxidase also confers 
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acidity to the substance. The pH range of honey is 3.2-4.5, which is low enough to be 
inhibitory to many bacterial pathogens. Moreover, research has shown that peripheral B 
lymphocytes and T lymphocytes proliferate in the presence of honey concentrations as low 
as 0.1%, and that phagocytes are activated by honey at these same low concentrations 
(Abbas, 1997). Our unit has succeeded in showing the advantageous effects of Medihoney in 
a randomised controlled trial comparing thrice weekly exit site application of standardised 
antibacterial honey versus 2% mupirocin ointment on infection rates in patients with cuffed 
tunnelled central venous catheters (Johnson et al., 2005). Topical Medihoney led to 
comparable rates of catheter-related infection compared to those achieved with mupirocin, 
but conferred additional benefits including low cost, an excellent safety profile and lack of 
antibiotic resistance, especially mupirocin resistance.  
4.6 Nasal eradication of S. aureus 
Historically, nasal carriage of S. aureus has been associated with greater bacteraemic 
episodes with S. aureus in haemodialysis patients (Yu et al., 1986). Patients on chronic 
haemodialysis have been reported to have over twice the rate of S. aureus nasal colonisation 
as healthy controls. More recent data are in agreement with this, and it is widely believed 
that nasal colonisation provides a natural reservoir that facilitates ongoing habitation and 
propagation of S. aureus in human populations. (Elie-Turenne et al., 2010; Mermel et al., 
2010). Nasal application of mupirocin has been proven to eradicate nasal carriage of S.aureus 
in up to 98.5% of cases (Taal et al., 2006). This strategy has been associated with a reduction 
in S. aureus bacteraemia compared to historical controls (Boelart et al., 1993), although again, 
use has been associated with the development of mupirocin resistance (Cavdar et al., 2004; 
Lobbedez et al., 2004). Currently however, there are no recommendations by the leading 
Nephrology bodies to perform routine eradication of nasal S.aureus in a bid to reduce 
catheter-related bacteraemia.  
4.7 The role of catheter design, structure and placement 
The first 30 days following catheter placement are vital to the prevention of bloodstream 
infection. During this period, technique should not be compromised as the main risk of 
entry is infection through medical staff interaction and the patient’s normal skin microflora. 
After this time, the catheter is more vulnerable to internal sources of infection, possibly via 
the catheter hub, leading to subsequent haematogenous spread and bloodstream infection. 
Alternatively, infection at a distant internal site may lead to colonisation of the indwelling 
catheter (Knuttinen et al., 2009).  
4.7.1 Tunnelled versus non-tunnelled catheters 
The incidence of bacteraemia is greatly reduced in subjects using cuffed tunnelled catheters 
as opposed to non cuffed catheters. The majority of modern cuffed tunnelled catheters are 
made of either polyurethane or silicone. The cuffed portion, which lies in the subcutaneous 
tissue near the insertion site, creates a fibrous seal and provides an effective barrier against 
infection by preventing migration of bacteria down the outer surface of the catheter. 
Although there are no prospective randomised trials investigating infection-related 
morbidity between catheter types in the dialysis population, observed bacteraemia rates 
range from 0.16–0.86 per 100 days with non-tunnelled non-cuffed dialysis catheter to 0.016–
0.27 per 100 days with tunnelled cuffed catheters. Evidence from the non-haemodialysis 
setting showed lower infection rates in tunnelled catheters (Andrivet et al., 1994; Timsit et 
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al., 2007). Within a set of immunocompromised patients, the rates of bacteraemia were 
reduced by cuffed catheters (2% vs 5%), although this did not achieve statistical significance 
(Andrivet et al., 1994). 
There is no clear evidence pointing to any differences in bacteraemia rates attained through 
usage of different catheter brands. Some groups have published data of long term tunnelled 
catheter usage (Tesio catheters, MedComp, Harleysville, Pennsylvania) highlighting 
bacteraemia rates similar to those achieved in arteriovenous fistulae. This particular group 
utilised strict protocols surrounding catheter care (Power et al., 2011). The four most 
commonly commercially available tunnelled catheters are the HemoSplit, Tesio twin 
catheter, Split-Catheter III and Permcath. A UK study examining catheter survival found 
that the Split Catheter III and Permcath fared worse than the HemoSplit and Tesio twin 
catheter. Infection rates were not specifically studied (Fry et al., 2008). 
4.7.2 Catheter placement 
There is no randomised trial evidence of any specific site of insertion conferring an 
increased risk of infection (Ruesch et al., 2002). In a large study of intensive care patients 
there was no statistically significant difference in the incidence of infection or duration of 
catheter amongst the insertion sites (Deshpande et al., 2005). Multivariate analyses from a 
number of studies have collectively suggested a higher rate of infection with the femoral 
vein location, with the infection risk with the jugular approach being greater than the 
subclavian approach (Breschan et al., 2007; Ishizuka et al., 2009, Ishizuka et al., 2008; 
Nagashima et al., 2006). These studies did not take into account baseline confounding 
variables. 
4.7.3 Catheter devices 
Trerotola et al.(2010) found no improvement in infection rates in tunnelled small bore 
central venous catheters with the insertion of a polyester cuff.  
4.7.4 Antibiotic-impregnated catheters 
Since the early 1990’s, there have been different types of central venous catheter antibiotic 
coatings trialled primarily in the critical care setting. There are no RCTs of antibiotic 
impregnated catheters in the chronic haemodialysis population. Raad et al. (1997) compared 
minocycline and rifampicin coated catheters head to head with untreated uncoated 
catheters, and found a significantly reduced rate of catheter related bacteraemia (0% versus 
5%, respectively). This was a double blinded study (n=281) where the antibiotic coated 
catheters had been pre-treated with tri-idodecyclmethylammoniumchloride surfactant. The 
minocycline and rifampicin components were both active against methicillin-sensitive and 
methicillin-resistant S. aureus, and also had reported activity against gram negative bacilli 
and Candida species. Within a multicentre study of intensive care units, Maki et al. (1997) 
found a higher degree of bacterial colonisation of the catheter material in the uncoated as 
compared to the antibiotic impregnated catheters.  
Following these results, the United States CDC recommended the use of antibiotic coated 
catheters for those with a high rate of infection after full adherence to other infection control 
measures, such as maximal sterile barrier precautions. There was also a recommendation 
that in an adult with an expected need for a central venous catheter for more than five days 
an antibiotic impregnated catheter be used in preference.  
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More recently, a large retrospective study of central venous catheters in the critical care 
setting showed that there was a significant reduced incidence of catheter-related infection 
that was independent and complementary to the infection control precautions utilised. The 
incidence improved from 8.3 episodes of infection per 1000 patient days to 1.2 episodes per 
100 patient days (Ramos et al., 2010). The body of evidence refers to only non-cuffed non-
tunnelled catheters, and has not led to the wide availability of such devices in the chronic 
haemodialysis population.  
4.8 Thrombolytic therapy 
Catheter-related bacteraemia may arise via the formation of an intraluminal thrombosis, 
which may then act as a nidus for the development of bacterial biofilm (McGee et al., 2003; 
Jain et al., 2009). Recombinant tissue plasminogen activator has been shown to be useful in 
catheter thrombus (Clase et al., 2001; Macrae et al., 2005; Tumlin et al., 2010) and some 
paediatric studies have looked into its potential effect on bacteraemia rates in the 
haemodialysis population. It has been shown that the prophylactic use of a catheter lock 
containing tissue plasminogen activator plus antibiotic can reduce the incidence of catheter–
related bacteraemia, and may improve the infection-free survival times of central catheters 
at high risk of infection (Onder et al., 2009).      
4.9 Aspirin 
In vitro and in vivo animal studies of infective endocarditis have demonstrated aspirin to 
have direct anti-staphylococcus effects. It is theorised that the salicylic component of aspirin, 
which is the major biometabolite, inhibits the expression of two key S. aureus virulence 
genes involved in endovascular pathogenesis. A retrospective observational study over 10 
years in a single haemodialysis centre found a lower rate of catheter-associated S. aureus 
bacteraemia in patients using aspirin at a daily dose of 325mg (Sedlacek et al., 2007).   
5. Conclusions 
The goal of treatment of patients with end-stage kidney failure is to provide optimal dialysis 
while at the same time averting excess morbidity and mortality. It should always be borne 
in mind that this patient group is a vulnerable and relatively immunosuppressed cohort, 
often with appreciably significant co-morbidity. Evidence points towards the best outcome 
being achieved when dialysis is initiated using a native arteriovenous fistula, with the next 
best outcome with an arteriovenous graft. However, concomitant disease burden can make 
native access formation challenging.     
The use of central venous catheters for dialysis purposes should be minimised and actively 
discouraged (ERBP Guidelines 2007, KDOQI 2006, CARI 2000) as they are associated with 
increased patient mortality, morbidity and cost of healthcare. The consequences of catheter-
related bacteraemia may be life-threatening, and could reach a 10% mortality rate (Saxena et 
al., 2002) and also effect cardiovascular morbidity. For those individuals where 
haemodialysis catheters are hard to avoid, a proactive approach is appropriate, and various 
preventative measures should be considered. The use of a catheter care protocol may be 
beneficial. The concept of the “care bundle” may be an extremely useful tool in the 
haemodialysis environment. In many ways the dialysis patient often has multi-organ 
involvement and a stepwise, astringent, highly protocolised pathway is appropriate. 
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Institution of such protocols has resulted in a drastic reduction in catheter-related 
bacteraemia reported in some American intensive care units (Pronovost et al., 2006).  
The use of antibiotic lock solutions and topical antimicrobial ointment (mupirocin, 
povidone-iodine and polysporin triple antibiotic) has been shown to be effective in reducing 
bacteraemia. The benefits of citrate locks have been demonstrated by two meta-analyses 
(Yahav et al., 2008; Labriola et al., 2008). However, there are tenable concerns regarding 
cardiac arrhythmias, which may be circumvented by using lower concentrations of citrate 
that may compromise their antimicrobial potency. Topical medical-grade honey has proved 
efficacious against exit site infection. Prophylactic antibiotic at the time of insertion is 
frequently administered, although this intervention has never been validated in randomised 
controlled trials (Ryan et al., 2004).  
Antibiotic coatings are in wide usage in the critical care arena using non-cuffed non-
tunnelled catheters, but their usage has not crossed over to the dialysis unit. Novel 
therapies, such as thrombolytic agents and aspirin, require larger randomised studies before 
their widespread use is advocated. 
We now have an increasing number of possible interventions in our armentarium to help us 
offer the best care to our patients. However, much more evidence in the form of clinical 
trials is needed to further elucidate the efficacy of these preventative measures, and other 
potential treatments.   
6. References 
Abbas T. (1997) Royal treat. Living in the Gulf; 50-1. 
Allon M. (2003). Prophylaxis against dialysis catheter related bacteraemia with a novel 
antimicrobial lock solution. Clinical  Infectious Disease; 36: 1539-1544. 
Allon M. (2008). Prophylaxis against dialysis catheter-related bacteraemia: a glimmer of 
 hope. American Journal of  Kidney Disease; 51: 165–168. 
Andrivet P, Bacquer A, Ngoc CV & Ferme C. (1994). Lack of clinical benefit from 
subcutaneous tunnel insertion of central venous catheters in immunocompromised 
patients. Clinical Infectious Diseases; 18(2): 199-206. 
ANZDATA Registry 2010 Report. (2010). The thirty third report.  
 http://www.anzdata.org.au/anzdata/AnzdataReport/33rdReport/ANZDATA33
 rdReport.pdf   
Ball PA, Brokenshire E, Parry B, Merrie A, Gillanders L, McIlroy K & Plank L. (2003). 
Ethanol locking as a possible treatment for microbial contamination of long-term 
central venous catheters. Nutrition; 19 (6):  570 
Barraclough KA, Hawley CM, Playford EG & Johnson DW. (2009). Prevention of access-
 related infections. Expert  Reviews in Anti-Infective Therapy; 7(10): 1185-200. 
Beathard GA & Urbanes A. (2008). Infection associated with tunnelled haemodialysis 
catheters. Seminars in  Dialysis; 21: 521-538.  
Betjes MGH & Van Agteren M. (2004). Prevention of dialysis catheter-related sepsis with a 
citrate-taurolidine-containing lock solution. Nephrology Dialysis Transplantation; 19: 
1546-1551. 
Bhat DJ, Tellis VA, Kohlberg WI, Driscoll B & Veith FJ. (1980). Management of sepsis 
involving expanded polytetrafluoroethylene grafts for haemodialysis access. 
Surgery; 87(4): 445-50. 
www.intechopen.com
 
Technical Problems in Patients on Hemodialysis 
 
100 
Birchenough E, Moore C, Stevens K, & Stewart S. (2010). Buttonhole cannulation in adult 
patients on haemodialysis:  an increased risk of infection?  Nephrology Nursing 
Journal; 37(5): 491-555. 
Bleyer AJ. (2007). Use of antimicrobial catheter lock solutions to prevent catheter-related 
bacteraemia. Clinical  Journal of the American Society of  Nephrology;  2(5): 1073-1078. 
Boddana P, Caskey F, Casula A & Ansell D. (2009). UK Renal Registry 11th Annual Report 
(December 2008): Chapter 14 UK Renal Registry and international comparisons. 
Nephron Clinical Practice;, 111 Suppl 1: c269-76. 
Boelaert JR, Van Landuyt HW, Godard CA Daneels RF, Schurgers ML, Matthys EG, De 
Baere YA, Gheyle DW, Gordts BZ & Herwaldt LA. (1993). Nasal mupirocin 
ointment decreases the incidence of Staphylococcus aureus bacteraemias in 
haemodialysis patients. Nephrology  Dialysis Transplantation; 8(3): 235-239.  
Breschan C, Platzer M, Jost R, Schaumberger F, Stettner H & Likar R. (2007). Comparison of 
catheter-related infection and tip colonization between internal jugular and 
subclavian central venous catheters in surgical neonates. Anesthesiology; 107(6): 946–
53. 
Broom JK, O'Shea S, Govindarajulu S, Playford G, Hawley CM, Isbel NM, Campbell SB, 
Mudge DW, Carpenter S, Johnson BC, Underwood N & Johnson DW (2009). 
Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial 
of Heparin versus EthAnol Lock THerapY for the prevention of Catheter 
Associated infecTion in Haemodialysis patients. BMC Nephrology; 10: 23 
Camins BC, Richmond AM, Dyer KL & Zimmerman HN. (2010). A crossover intervention 
trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing 
catheter-related bloodstream infections among patients undergoing haemodialysis. 
Infection Control and Hospital Epidemiology; 31(11): 1118-23. 
CARI (Caring for Australasians with Renal Impairment) Guidelines. (2000). Dialysis Guidelines: 
Vascular Access. Available at www.cari.org.au 
Cavdar C, Atay T, Zeybel M, Celik A, Ozder A, Yildiz S, Gulay Z & Camsari T. (2004). 
Emergence of resistance in staphylococci after long-term mupirocin application in 
patients on continuous ambulatory peritoneal dialysis. Advances in  Peritoneal 
Dialysis;  20: 67-70.  
Clase CM, Crowther MA, Ingram AJ & Cina CS. (2001). Thrombolysis for restoration of 
patency to haemodialysis central venous catheters: a systemic review. Journal of 
Thrombosis and Thrombolysis; 11: 127-36.  
Del Rio A, Cervera C, Moreno A, Moreillon P & Miro JM. (2009). Patients at risk of 
complications of Staphylococcus aureus bloodstream infection. Clinical Infectious 
Disease; 48(4): S246–S253. 
Deshpande KS, Hatem C, Ulrich HL & Currie BP. (2005). The incidence of infectious 
complications of central venous catheters at the subclavian, internal jugular, and 
femoral sites in an intensive care unit population. Critical Care Medicine; 33: 13–20. 
Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF & Port FK. (2001). Type of vascular 
access and mortality in US haemodialysis patients. Kidney International 2001; 60(4): 
1443–51. 
Dogra GK, Herson H, Hutchison B, Irish AB, Heath CH, Golledge C, Luxton G & Moody H. 
(2002) . Prevention of tunnelled haemodialysis catheter-related infections using 
catheter-restricted filling with gentamicin and citrate: a randomized controlled 
study. Journal of the American Society of  Nephrology; 13(8): 2133-9. 
www.intechopen.com
 
Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention  
 
101 
Doss S, Schiller B, Moran J. (2008). Buttonhole cannulation – an unexpected outcome. 
Nephrology Nursing Journal; 35(4): 417-419.  
Droste JC, Jeraj HA, MacDonald A & Farrington K. (2003). Stability and in vitro efficacy of 
antibiotic-heparin lock solutions potentially useful for treatment of central venous 
catheter-related sepsis. Journal of Antimicrobial Chemotherapy; 51: 849–855. 
Dryden MS, Samson A, Ludlam HA, Wing AJ & Phillips I. (1991). Infective complications 
associated with the use of Quinton Permcath for long-term central vascular access 
in haemodialysis. Journal of Hospital Infection; 19: 257–262. 
Eknoyan G, Beck GH, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, 
Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco 
MV, Schulman G, Schwab SJ, Teehan BP & Toto R; Hemodialysis (HEMO) Study 
Group. (2002). Effect of dialysis dose and membrane flux in maintenance 
haemodialysis. New England Journal of  Medicine; 347: 2010–2019. 
Elie-Turenne MC, Fernandes H, Mediavilla JR, Rosenthal M, Mathema B, Singh A, Cohen 
TR, Pawar KA, Shahidi H, Kreiswirth BN, & Deitch EA. (2010). Prevalence and 
characteristics of Staphylococcus aureus colonization among healthcare professionals 
in an urban teaching hospital. Infection Control and Hospital  Epidemiology;  31: 574–
580. 
Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T, Akiba T, Canaud BJ & Pisoni 
RL. (2008). Vascular access use and outcomes: an international perspective from the 
dialysis outcomes and practice patterns study. Nephrology Dialysis Transplantation; 
23: 3219–3226. 
Fistula First Breakthrough Initiative (FFBI). (2007). Summary of the FFBI buttonhole 
technique environmental scan. http://www.fistulafirst.org. 
Fry AC, Stratton J, Farrington K & Mahna K. (2008). Factors affecting long-term survival of 
tunnelled haemodialysis catheters—a prospective audit of 812 tunnelled catheters. 
Nephrology Dialysis Transplantation; 23(1):  275-281.  
Fux CA, Stoodley P, Hall-Stoodley L & Costerton JW. (2003). Bacterial biofilms: a diagnostic 
and therapeutic challenge. Expert Reviews in Anti-Infective Therapy; 1: 667–683. 
Gould IM. (2007). MRSA bacteraemia. International Journal of  Antimicrobial Agents; 30(Suppl 
 1): S66–S70. 
Guenu S, Heng AE, Charbonne F, Galmier MJ, Charles F, Deteix, Souweine B & Lartigue C. 
(2007). Mass spectrometry and scanning electron microscopy study of silicone 
tunnelled dialysis catheter integrity after an exposure of 15 days to 60% ethanol 
solution. Rapid Commununications in Mass Spectrometry;  21:229-236. 
Hartig V & Smyth W. (2009). Everyone should buttonhole: a novel technique for a regional 
Australian renal service. Journal of  Renal Care; 35(3): 114-9. 
Hoen B, Paul-Dauphin A, Hestin D & Kessler M. (1998). EPIBACDIAL: a multicenter 
prospective study of risk factors for bactaeremia in chronic haemodialysis patients. Journal 
of the American Society of Nephrology;  9: 869-876. 
Ishani R, Collins AJ, Herzog C & Foley R. (2005). Septicaemia, access and cardiovascular 
disease in dialysis patients: The USRDS Wave 2 Study. Kidney International;  68: 
311–318. 
Ishizuka M, Nagata H, Takagi K & Kubota K. (2009). Femoral venous catheterization is a 
major risk factor for central venous catheter-related bloodstream infection. Journal 
of  Investigative Surgery; 22: 16–21. 
www.intechopen.com
 
Technical Problems in Patients on Hemodialysis 
 
102 
Ishizuka M, Nagata H, Takagi K, Horie T, Furihata M, Nakagawa A & Kubota K. (2008). 
External jugular Groshong catheter is associated with fewer complications than a 
subclavian Argyle catheter. European Surgical Research; 40: 197–202. 
Jaffer Y, Selby NM, Taal MW, Fluck RJ & McIntyre CW. (2008). A meta-analysis of 
haemodialysis catheter locking solutions in the prevention of catheter-related 
infection. American Journal of Kidney Disease; 51: 233–241. 
Jain G, Allon M, Saddekni S, Barker JF & Maya ID. (2009). Does heparin coating improve 
patency or reduce infection of tunnelled dialysis catheters? Clinical Journal of the 
American Society of Nephrology; 4: 1787-90. 
James MT, Conley J, Tonelli M, Manns BJ, MacRae J & Hemmelgarn BR. (2008). Meta-
analysis: antibiotics for prophylaxis against  haemodialysis catheter-related 
infections. Alberta Kidney Disease Network. Annals of  Internal Medicine; 148(8): 
596-605. 
Johnson DW, MacGinley R, Kay TD, Hawley CM, Campbell SB, Isbel NM & Hollett P. 
(2002). A randomised controlled trial of topical exit-site mupirocin application in 
patients with tunnelled cuffed haemodialysis catheters. Nephrology Dialysis 
Transplantation; 17: 1802-1807. 
Johnson DW, Van Eps C, Mudge DW, Wiggins KJ, Armstrong K & Hawley CM. (2005). 
Randomized, controlled trial of topical exit-site application of honey (Medihoney) 
versus mupirocin for the prevention of catheter-associated infections in 
haemodialysis patients. Journal of the  American Society of  Nephrology; 16: 1456–1462.  
KDOQI 2006: National Kidney Foundation. (2006). Clinical practice guidelines and clinical 
practice for vascular access. http://www.kidney.org/professionals/kdoqi/ 
guideline˙upHD˙PD˙VA/index.htm  
Knuttinen M, Bobra S, Hardman J & Gaba R. (2009). A review of evolving dialysis catheter 
 technologies. Seminars in Interventional Radiology;  26 (2): 106-114. 
Labriola L, Crott R & Jadoul M. (2008). Preventing haemodialysis catheter-related 
bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective 
randomized trials. Nephrology Dialysis Transplantation; 23: 1666–1672. 
Landry DL, Braden GL, Gobeille SL & Haessler SD. (2010). Emergence of gentamicin-
resistant bacteraemia in haemodialysis patients receiving gentamicin lock catheter 
prophylaxis. Clinical Journal of the American Society of  Nephrology; 5 (10) : 1799-1804. 
Lee D, Jung K & Choi Y. (2008). Use of maximal sterile barrier precautions and/or 
antimicrobial-coated catheters to reduce the risk of central venous catheter–related 
bloodstream infection. Infection Control and Hospital Epidemiology; 29(10): 947-950. 
Levin A, Mason AJ, Jindal KK, Fong IW & Goldstein MB. (1991). Prevention of 
haemodialysis subclavian vein catheter infections by topical povidone-iodine. 
Kidney International; 40(5): 934–8. 
Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Izatt S, Bargman JM, Jassal SV, Vas S, 
Brunton J & Oreopoulos DG. (2004). Routine use of mupirocin at the peritoneal 
catheter exit site and mupirocin resistance: still low after 7 years. Nephrology 
Dialysis Transplantation; 19(12): 3140-3143. 
Ludlow V. (2010). Buttonhole cannulation in haemodialysis: improved outcomes and 
increased expense – is it worth it? Canadian Association of Nephrology Nurses and 
Technologists Journal; 20(1): 29-37. 
Macrae JM, Loh G, Djurdjev, Shalansky S, Werb R, Levin A, Kiaii M. (2005). Short and long 
alteplase dwells in dysfunctional haemodialysis catheters. Haemodialysis 
International; 9: 189-95. 
www.intechopen.com
 
Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention  
 
103 
Maharaj AR, Zelenitsky SA & Vercaigne LM. (2008). Effect of an ethanol/trisodium citrate 
hemodialysis catheter locking solution on isolated of Candida albicans. 
Haemodialysis International; 12(3): 342-327. 
Maki DG, Stolz SM, Wheeler S & Mermel LA. (1997). Prevention of central venous catheter-
related bloodstream infection by use of an antiseptic impregnated catheter: a 
randomized, controlled trial. Annals of Internal Medcine; 127: 257-66. 
Marr KA, Sexton D, Conlon PJ Corey GR, Schwab SJ & Kirkland K. (1997). Catheter-related 
bacteraemia and outcome of attempted catheter salvage in patients undergoing 
haemodialysis. Annals of Internal Medicine; 127: 275–280.  
Maya ID, Carlton D, Estrada E & Allon M. (2007). Treatment of dialysis catheter-related 
Staphylococcus aureus bactaeremia with an antibiotic lock: a quality improvement 
report. American Journal of Kidney Disease; 50(2): 289-95. 
McCann M & Moore ZE. (2010). Interventions for preventing infectious complications in 
haemodialysis patients with central venous catheters. Cochrane Database Systematic 
Review; 20(1): CD00689. 
Mcgee DC & Gould MK. (2003). Preventing complications of central venous catheterisation. 
New England Journal of Medicine; 348: 1123-1133.  
Mermel LA, Eells SJ, Acharya MK, Cartony JM, Dacus D, Fadem S, Gay EA, Gordon S, 
Lonks JR, Perl TM, McDougal LK, McGowan JE, Maxey G, Morse D & Tenover FC. 
(2010). Quantitative analysis and molecular fingerprinting of methicillin-resistant 
Staphylococcus aureus nasal colonization in different patient populations: a 
prospective, multicenter study. Infection Control and Hospital Epidemiology;  31: 592–
597.  
Metcalf SCL, Chambers ST & Pithie AD. (2004). Use of ethanol locks to prevent recurrent 
central line sepsis. Journal of  Infection; 49: 20–22. 
Moist LM, Trpeski L, Na Y & Lok CE. (2008). Increased haemodialysis catheter use in 
Canada and associated mortality risk: data from the Canadian Organ Replacement 
Registry 2001–2004. Clinical Journal of the American Society of Nephrology; 3: 1726–
1732. 
Mokrzycki MH, Jean-Jerome K, Rush H, Zdunek MP & Rosenberg SO. (2001). A randomized 
trial of minidose warfarin for the prevention of late malfunction in tunnelled, 
cuffed haemodialysis catheters. Kidney International; 59: 1935–1542. 
Mokrzycki MH, Schroppel B, von Gersdorff G, Rush H, Zdunek M & Feingold R. (2000). 
Tunnelled cuffed catheter associated infections in haemodialysis patients 
seropositive for the human immunodeficiency virus. Journal of the American Society 
of Nephrology; 11: 2122–2127. 
Moss AH, Vasilakis C, Holley JL, Foulks CJ, Pillai K & McDowell DE. (1990). Use of a 
silicone dual-lumen catheter with a Dacron cuff as a long-term vascular access for 
haemodialysis patients. American Journal of Kidney Disease; 16: 211-215.  
Nagashima G, Kikuchi T, Tsuyuzaki H, Kawano R, Tanaka H, Nemoto H, Taguchi K & 
Ugajin K. (2006). To reduce catheter-related bloodstream infections: is the 
subclavian route better than the jugular route for central venous catheterization? 
Journal of Infection and  Chemotherapy;  12: 363–5. 
National Kidney Foundation KDOQI. (2001). Clinical practice guidelines and clinical 
practice for vascular access, update 2006. http://www.kidney.org/professionals/ 
kdoqi/guideline˙upHD˙PD˙VA/index.htm  
Nesrallah GE, Cureden M, Wong JHS & Pierratos A. (2010). Staphylococcus aureus 
bacteraemia and buttonhole cannulation:  long-term safety and efficacy of 
www.intechopen.com
 
Technical Problems in Patients on Hemodialysis 
 
104 
mupirocin prophylaxis. Clinical Journal of the  American Society of  Nephrology; 5(6): 
1047-53. 
Nielsen J, Kolmos HJ & Espersen F. (1998). Staphylococcus aureus bacteraemia among patients 
undergoing dialysis—focus on dialysis catheter-related cases. Nephrology Dialysis 
Transplantation; 13: 139–145. 
Onder AM, Chandar J, Billings A, Simon N, Gonzalez J, Francoeur D, Abitbol C & Zilleruelo 
G. (2009). Prophylaxis of catheter-related bacteremia using tissue plasminogen 
activator-tobramycin locks. Pediatric Nephrology; 24(11): 2233-43. 
Pastan S, Soucie JM & McClellan WM. (2002). Vascular access and increased risk of death 
among haemodialysis patients. Kidney International; 62(2): 620–6. 
Pennington CR & Pithie AD. (1987). Ethanol lock in the management of catheter occlusion. 
Journal of  Parenteral Nutrition; 11: 507–5083.  
Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, 
Goodkin DA & Held PJ. (2002). Vascular access use in Europe and the United 
States: Results from the DOPPS. Kidney International; 61(1): 305–16.  
Polkinghorne KR, McDonald SP, Atkins RC & Kerr PG. (2004). Vascular access and all cause 
mortality: a propensity score analysis. Journal of the American Society of Nephrology; 
15(2): 477–86. 
Power A, Duncan N, Singh SK, Brown W, Dalby E, Edwards C, Lynch K, Prout V, Cairns T, 
Griffith M, McLean A, Palmer A & Taube D. (2009). Sodium citrate versus heparin 
catheter locks for cuffed central venous catheters: a single center randomised 
control trial of sodium citrate versus heparin line locks for cuffed central venous 
catheters. American Journal of Kidney Disease; 53(6): 1034-1041. 
Power A, Singh SK, Ashby D, Cairns T, Taube D & Duncan N. (2011). Long-term Tesio 
catheter access for haemodialysis can deliver high dialysis adequacy with low 
complication rates. Journal of Vascular and Interventional Radiology; 22(5): 631-637 
Pronovost PJ, Holzmueller CG, Clattenburg L, Berenholtz S, Martinez EA, Paz JR& 
Needham DM. (2006). Team care: beyond open and closed intensive care units. 
Current Opinion in Critical Care; 12(6): 604-8. 
Pronovost PJ, Goeschel CA, Colantuoni E, Watson S, Lubomski LH, Berenholtz SM, 
Thompson DA, Sinopoli DJ, Cosgrove S, Sexton JB, Marsteller JA, Hyzy RC, Welsh 
R, Posa P, Schumacher K & Needham D. (2010). Sustaining reductions in catheter 
related bloodstream infections in Michigan intensive care units: observational 
study. British Medical Journal; 4;340: 309-315 
Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J, 
Buzaid A, Robertson C, Shenaq S, Curling P, Burke T & Ericsson C. (1997). Central 
venous catheters coated with minocycline and rifampin for the prevention of 
catheter-related colonization and bloodstream infections: a randomized, double-
blind trial. Annals of Internal Medicine; 127: 267-74. 
Rabindranath KS, Bansal T, Adams J, Das R, Shail R, MacLeod AM, Moore C & Besarab A. 
(2009). Systematic review of antimicrobials for the prevention of haemodialysis 
catheter-related infections. Nephrology Dialysis Transplantation; 24(12): 3763-74. 
Ramos ER, Reitzel R, Jiang Y, Hachem RY, Chaftari AM, Chemaly RF, Hackett B, 
Pravinkumar SE, Nates J, Tarrand JJ & Raad II. (2010). Clinical effectiveness and 
risk of emerging resistance associated with prolonged use of antibiotic-
impregnated catheters: More than 0.5 million catheter days and 7 years of clinical 
experience. Critical Care Medicine; 39 (2): 245 -251. 
www.intechopen.com
 
Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention  
 
105 
Regamey C, Schaberg D & Kirby WM. (1972). Inhibitory effect of heparin on gentamicin 
concentrations in blood. Antimicrobial Agents and Chemotherapy; 1: 329–332. 
Ruesch S, Walder B & Tramer MR. (2002). Complications of central venous catheters: 
 internal jugular versus  subclavian access—a systematic review. Critical Care 
 Medicine; 30: 454–60. 
Ryan JM, Ryan BM & Smith TP. (2004). Antibiotic prophylaxis in interventional radiology. 
Journal of Vascular and Interventional Radiology; 15(6): 547-56. 
Saad TF. (1999). Bacteraemia associated with tunnelled, cuffed haemodialysis catheters. 
American Journal of Kidney Disease; 34: 1114–1124.  
Saxena AK, Panhotra BR, Uzzaman W, & Venkateshappa CK. (2002). The role of the 
 Staphylococcus aureus nasal carriage and type of vascular access in the outcome of 
high-risk patients on haemodialysis. Journal of Vascular Access; 3(2): 74-9 
Sedlacek M, Gemery JM, Cheung AL, Bayer AS & Remillard BD. (2007). Aspirin treatment is 
associated with a significantly decreased risk of staphylococcus aureus bactaeremia in 
haemodialysis patients with tunnelled catheters. American Journal of Kidney Diseases; 
49: 401-408. 
Shanks RM, Sargent L, Martinez RM, Graber M & O’Toole G. (2006). Catheter lock solutions 
influence staphylococcal biofilm formation on abiotic surfaces. Nephrology Dialysis 
Transplantation; 21: 2247–2255. 
Silva GD, Silva RA, Niccolino AM, Pavanetti LC, Alasmar VL, Guzzardi R, Zanolli MB, 
Guilhen JC & Araujo ID. (2010). Initial experience with the buttonhole technique in 
a Brazilian haemodialysis center. Journal of  Brasilian Nefrology; 32(3): 257-62. 
Solomon LR, Cheesbrough JS, Ebah L & Al-Sayed T. (2010) . A randomized double-blind 
controlled trial of taurolidine-citrate catheter locks for the prevention of 
bacteraemia in patients treated with haemodialysis. American Journal of Kidney 
Diseases; 55 (6): 1060-1068. 
Taal MW, Fluck RJ & McIntyre CW. (2006). Preventing catheter related infections in 
haemodialysis patients. Current Opinion in Nephrology and Hypertension; 15(6): 599-
602. 
Takla TA, Zelenitsky SA & Vercaigne LM. (2007). Effect of ethanol/trisodium lock on 
microorganisms causing haemodialysis related catheter infections. Journal of 
Vascular Access; 8(4): 262-7. 
Taylor C, Cahill J, Gerrish M, & Little J. (2008). A new haemodialysis catheter-locking agent 
reduces infections in haemodialysis patients. Journal of Renal Care; 34(3): 116-120. 
The European Renal Association - European Dialysis and Transplant Association. European 
best practice guidelines for haemodialysis (Part 1) ERA-EDTA. (2002). Nephrology 
Dialysis Transplantation; 17: (Suppl 7):1–111. 
Timsit JF, Schwebel C, Bouadma L & Geffroy A. (2009). Chlorhexidine-impregnated sponges 
and less frequent dressing changes for prevention of catheter-related infections in 
critically ill adults: a randomized controlled trial. Journal of the American Medical 
Association; 25: 301(12): 1231-41. 
Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Kooman J, Martin-Malo A, 
Pedrini L, Pizzarelli F, Tattersall J, Vennegoor M, Wanner C, ter Wee P & 
Vanholder R. (2007). EBPG on Vascular Access. Nephrology Dialysis Transplantation; 
22 [Suppl 2]:  ii88–ii117.  
Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris MG, Wennersten CB, 
Sofia RD & Eliopoulos GM. (2000). Activities of taurolidine in vitro and in 
www.intechopen.com
 
Technical Problems in Patients on Hemodialysis 
 
106 
experimental enterococcal endocarditis. Antimicrobial Agents and Chemotherapy; 
44(6): 1720-1724. 
Trerotola SO, Patel AA, Shlansky-Goldberg RD, Solomon JA, Mondschein JI, Stavropoulos 
SW, Soulen MC, Itkin M & Chittams J. (2010). Short-term infection in cuffed versus 
noncuffed small bore central catheters: a randomized trial. Journal of Vascular and 
Interventional Radiology; 21: 203–11. 
Tumlin J, Goldman J, Spiegel DM, Roer D, Ntoso KA, Blaney M, Jacobs J, Gillespie BS & 
Begelman SM. (2010). A phase III, randomised, double-blind placebo-controlled 
study of tenecteplase for improvement of haemodialysis catheter function: 
TROPICS 3. Clinical Journal of the American Society of Nephrology; 5: 631-6. 
United States CDC (Centers for Disease Control and Prevention). Guidelines for the 
prevention of intravascular catheter-related infections (2002).  
 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm : 1–26. 
Van Eps CL, Jones M, Ng T, Johnson DW, Campbell SB, Isbel NM, Mudge DW, Beller E & 
Hawley CM. (2010). The impact of extended-hours home haemodialysis and 
buttonhole cannulation technique on hospitalization rates for septic events related 
to dialysis access. Haemodialysis International; 14(4): 451-63. 
Van Loon MM, Goovaerts T, Kessels AGH, van der Sande FM & Tordoir JHM. (2010). 
Buttonhole needling of haemodialysis arteriovenous fistulae results in less 
complications and interventions compared to the rope-ladder technique. Nephrology 
Dialysis Transplantation; 25: 225-30. 
Vercaigne LM, Takla TA & Raghavan J. (2010). Long-term effect of an ethanol/sodium 
citrate solution on the mechanical properties of haemodialysis catheters. Journal of  
Vascular Access; 11(1): 12-6. 
Weijmer MC, van den Dorpel MA, Van de Ven PJG, ter Wee P, van Geelen J, Groeneveld J,  
van Jaarsveld BC, Koopmans M,  le Poole C, Schrander A, Sieger C & Stas KJ. 
(2005). Randomized, clinical trial comparison of trisodium citrate 30% and heparin 
as catheter-locking solution in haemodialysis patients. Journal of the American Society 
of Nephrology;  16: 2769-2777. 
Xue J, Dahl D, Ebben J & Collins AJ. (2003). The association of initial haemodialysis access 
type with mortality outcomes in elderly Medicare ESRD patients. American Journal 
of Kidney Diseases; 42(5): 1013-1019. 
Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U & Paul M. (2008). Antimicrobial 
lock solutions for the prevention of infections associated with intravascular 
catheters in patients undergoing haemodialysis: systematic review and meta-
analysis of randomized, controlled trials. Clinical Infectious Diseases; 47: 83–93.  
Yoo S, Ha M, Chio D & Pai H. (2001). Effectiveness of surveillance of central catheter-related 
bloodstream infection in an ICU in Korea. Infection Control and Hospital 
Epidemiology; 22: 433–436. 
Yu VL, Goetz A & Wagener M. (1986). Staphylococcus aureus carriage and infection in 
patients on haemodialysis. Efficacy of antibiotic prophylaxis. New England Journal of  
Medicine; 315: 91–96.  
www.intechopen.com
Technical Problems in Patients on Hemodialysis
Edited by Prof. Maria Goretti Penido
ISBN 978-953-307-403-0
Hard cover, 312 pages
Publisher InTech
Published online 07, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book provides an overview of technical aspects in treatment of hemodialysis patients. Authors have
contributed their most interesting findings in dealing with hemodialysis from the aspect of the tools and
techniques used.Each chapter has been thoroughly revised and updated so the readers are acquainted with
the latest data and observations in the area, where several aspects are to be considered. The book is
comprehensive and not limited to a partial discussion of hemodialysis. To accomplish this we are pleased to
have been able to summarize state of the art knowledge in each chapter of the book.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Nirosha D. Gunatillake, Elizabeth M. Jarvis and David W. Johnson (2011). Hemodialysis Access Infections,
Epidemiology, Pathogenesis and Prevention, Technical Problems in Patients on Hemodialysis, Prof. Maria
Goretti Penido (Ed.), ISBN: 978-953-307-403-0, InTech, Available from:
http://www.intechopen.com/books/technical-problems-in-patients-on-hemodialysis/hemodialysis-access-
infections-epidemiology-pathogenesis-and-prevention
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
